Please ensure Javascript is enabled for purposes of website accessibility

3 Top Stocks Under $10

By Taylor Carmichael - Jun 24, 2021 at 9:03AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Are you looking for cheap stocks with a lot of upside? Check out Rolls-Royce, Pieris Pharmaceuticals, and Kahoot!

Why do some stocks trade in the single digits? Often a stock is cheap because it's a loser company, and the market has priced it accordingly. It's always dangerous investing in subpar penny stocks. 

On the other hand, the market is not omniscient. Sometimes stocks you want to own are surprisingly cheap. For instance, if a strong company has a really bad year because of COVID-19, its stock price can be hammered. That's what happened to shares of Rolls-Royce (RYCEY 1.40%).

Or a micro-cap biotech can have some amazing news and the market is oblivious. I think that's the situation with Pieris Pharmaceuticals (PIRS 0.64%).

Or you might find a company that's not cheap at all -- it's just the share price that's a bargain. For instance Kahoot! (KHOT.F 4.95%) has a price-to-sales ratio of 76. So it's a highly expensive stock that's trading for $7.

All three of these stocks are buys, in my opinion. Here's why I'm bullish.

Mechanic works on a jet engine.

Image source: Getty Images.

1. Rolls-Royce will come back

Back in 2019, shares of British aerospace giant Rolls-Royce changed hands at over $12 a share. Now you can buy a share for a little over $1.50. To say that COVID-19 hurt this company is an understatement. In 2020, the aviation industry was shut down around the world. At one point, American aerospace giant Boeing lost about 75% of its market cap. It's been a bloodbath for the whole sector.

RYCEY Chart

RYCEY data by YCharts

Of course, Rolls-Royce is far from a microcap, even after its stock was obliterated. Despite its penny-stock status, the company has a $13 billion market cap. What sent the share price so low was a massive share offering last year that diluted existing shareholders. The company felt the need to do that as it was bleeding cash. The business had negative cash flow of 2.8 billion pounds (about $3.9 billion) in the first half of 2020. So Rolls did a secondary offering, diluting existing shareholders about 77%.

Not surprisingly, Rolls also suspended its dividend for the first time since 1987. So existing shareholders have been disappointed by the company, and I don't blame anyone for skedaddling. But for outsiders who have been watching from a distance, Rolls stock is looking pretty interesting.

This is a company that's been around since the 19th century. The company's Silver Ghost was hailed as "the best car in the world" in 1906. Rolls built the engine for the Submarine Spitfire, the plane that defeated Adolf Hitler in the air over London in World War II. In 1953, Rolls entered the civil aviation market. In 1960, the company introduced the world's first turbofan jet engine. Now it's one of the largest manufacturers of jet engines in the world. (Rolls sold off its car business in 1998.)  

The company has reduced its burn rate by 1 billion pounds, while simultaneously acquiring an additional 7 billion pounds in liquidity. That's more than enough to carry it through the pandemic. Management predicts the company will be cash flow positive next year. Investors willing to take a little risk now should be rewarded handsomely as the aviation market opens up again.  

2. This micro-cap biotech has a lot of big-name partners

If you're buying a biotech without profits and revenue -- a highly risky thing to do -- it's probably a good idea to shop in the cheap section. These are the stocks that Wall Street is ignoring. So while value investors like Warren Buffett wouldn't touch biotech stocks with a 10-foot pole, you can nonetheless do very well by thinking like a value investor in this sector.

Pieris Pharma has a $240 million market cap and is trading for $3 a share. It's a quintessential tiny biotech company, and Wall Street isn't paying any attention. But a lot of other biotech companies are noticing Pieris, and they want to develop drugs with the company.

Pieris has collaboration agreements with AstraZeneca, Boston Pharmceuticals, Servier, and Seagen. And it just signed a major deal with Genentech, now part of Roche.

What's generating this desire to collaborate with Pieris is the biotech's focus on lipocalins, proteins that naturally bind and transport molecules throughout the human body. The biotech has developed its proprietary Anticalin tech based on its scientific discoveries. Pieris has two main focuses right now: cancer and respiratory diseases. 

Pieris has received $175 million in upfront and milestone payments so far from its biotech partners. While it's early in this company's journey (its lead molecule is in phase 2), the company might receive almost $9 billion if future milestones are met. And that does not include royalties if the drugs are successful. Pieris also has two drugs that it's kept in-house, including its lead oncology molecule, PRS-343, about to enter phase 2 trials later this year.

Kahoot! is making education fun

Kahoot! is a software-as-a-service (SaaS) company based in Norway. The company offers a gaming platform that makes education a competitive sport. Over 1.5 billion people around the world have played a Kahoot! These are visual and colorful multiple-choice trivia games in subjects like music, sports, hard sciences, and world history. 

The company has a freemium model that allows you to play for free, advance to the family plan for $5 a month, or choose premier play at $15 a month. On the corporate side, Kahoot! offers corporate trainers and presenters a variety of software plans from $17 a month (20 participants) up to $59 a month (2,000 participants). Ninety-seven percent of the companies in the Fortune 500 use Kahoot!   

Right now the company has 500,000 paying users. Revenue is still low, at $45 million last year, but it's growing fast, at a 300% clip. Kahoot! estimates its market opportunity at $20 billion. Softbank has invested $215 million in the company. Microsoft and Walt Disney are also investors. 

While there's always a risk in buying cheap stocks, if your investment thesis is right, the upside is huge. I believe these companies are undervalued right now and will outperform the market going forward.

Teresa Kersten, an employee of LinkedIn, a Microsoft subsidiary, is a member of The Motley Fool's board of directors. Taylor Carmichael owns shares of Kahoot! AS, Pieris Pharmaceuticals, and Walt Disney. The Motley Fool owns shares of and recommends Kahoot! AS, Microsoft, and Walt Disney. The Motley Fool recommends Seagen Inc. and Softbank Group. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rolls-Royce Holdings plc Stock Quote
Rolls-Royce Holdings plc
RYCEY
$1.08 (1.40%) $0.01
The Boeing Company Stock Quote
The Boeing Company
BA
$169.99 (1.26%) $2.11
Microsoft Corporation Stock Quote
Microsoft Corporation
MSFT
$291.91 (1.70%) $4.89
The Walt Disney Company Stock Quote
The Walt Disney Company
DIS
$121.57 (3.30%) $3.88
Roche Holding AG Stock Quote
Roche Holding AG
RHHBY
$42.00 (2.34%) $0.96
Seagen Inc. Stock Quote
Seagen Inc.
SGEN
$170.14 (-2.24%) $-3.90
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$66.64 (3.08%) $1.99
SoftBank Group Corp. Stock Quote
SoftBank Group Corp.
SFTB.Y
$20.90 (1.95%) $0.40
Pieris Pharmaceuticals, Inc. Stock Quote
Pieris Pharmaceuticals, Inc.
PIRS
$1.57 (0.64%) $0.01
Kahoot! AS Stock Quote
Kahoot! AS
KHOT.F
$2.97 (4.95%) $0.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.